Lipid Luminations

Keys to the Latest NLA Recommendations for Dyslipidemia Treatments

September 9, 201415 min
Host: Alan S. Brown, MD, FNLA What's the evidence for LDL and other non-HDL targets for primary and secondary prevention of heart disease? What are the comparative benefits versus toxicities of all lipid-lowering medications in clinical use? Addressing these and other questions from the standpoing of recent NLA recommendations is Kevin Maki, PhD, FNLA, CLS, Chief Science Officer for Midwest Center for Metabolic and Cardiovascular Research and Adjunct Faculty in Biostatistics and Applied Epidemiology at DePaul University, Chicago, IL. Produced in partnership with

Chat About Keys to the Latest NLA Recommendations for Dyslipidemia Treatments